Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

著者: Georgina V. Long, Robyn P.M. Saw, Serigne Lo, Omgo E. Nieweg, Kerwin F. Shannon, Maria Gonzalez, Alexander Guminski, Jenny Lee, Hansol Lee, Peter M. Ferguson, Robert V. Rawson, James S. Wilmott, John F. Thompson, Richard Kefford, Sydney Ch’ng, Jonathan R. Stretch, Louise Emmett, Rony Kapoor, Helen Rizos, Andrew J. Spillane, Richard A. Scolyer, Alexander M. Menzies - The Lancet 2019 被引用: 185